Treatment of vitamin D depletion after Roux-en- Y gastric bypass: a randomized prospective clinical trial
Abstract Background A high prevalence (60%) of vitamin D (VitD) depletion, defined as a serum 25-hydroxyvitamin D level of ≤20 ng/mL, is present in preoperative morbidly obese patients. Despite daily supplementation with 800 IU VitD and 1500 mg calcium after Roux-en- Y gastric bypass (RYGB), VitD de...
Gespeichert in:
| Veröffentlicht in: | Surgery for obesity and related diseases 2009-07, Vol.5 (4), p.444-449 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 449 |
|---|---|
| container_issue | 4 |
| container_start_page | 444 |
| container_title | Surgery for obesity and related diseases |
| container_volume | 5 |
| creator | Carlin, Arthur M., M.D Rao, D. Sudhaker, M.B.B.S., F.A.C.P., F.A.C.E Yager, Kelli M., M.S., M.P.H Parikh, Nayana J., B.Sc Kapke, Alissa, M.S |
| description | Abstract Background A high prevalence (60%) of vitamin D (VitD) depletion, defined as a serum 25-hydroxyvitamin D level of ≤20 ng/mL, is present in preoperative morbidly obese patients. Despite daily supplementation with 800 IU VitD and 1500 mg calcium after Roux-en- Y gastric bypass (RYGB), VitD depletion persists in almost one half (44%) of patients. However, the optimal management of VitD depletion after RYGB and the potential benefits of such treatment are currently unknown. Methods A total of 60 VitD-depleted morbidly obese women were randomly assigned to receive 50,000 IU of VitD weekly after RYGB (group 1; n = 30) or no additional VitD after RYGB (group 2; n = 30). All patients received a daily supplement of 800 IU VitD and 1500 mg calcium. The serum calcium, parathyroid hormone, 25-hydroxyvitamin D, bone-specific alkaline phosphatase, urinary N -telopeptide, and bone mineral density were measured preoperatively and 1 year after RYGB. Questionnaires were used to assess other potential sources of VitD, including sunlight exposure and ingestion of VitD-containing foods/liquids. Results At 1 year after RYGB, VitD depletion and mean 25-hydroxyvitamin D level had improved significantly in group 1 (14% and 37.8 ng/mL, respectively) compared with the values in group 2 (85% and 15.2 ng/mL, respectively; P |
| doi_str_mv | 10.1016/j.soard.2008.08.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67528527</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1550728908006230</els_id><sourcerecordid>67528527</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-bbcdd30c6175e49bc0083c69c7926cdb832a8cbfec4ac6a8c984876516759a9f3</originalsourceid><addsrcrecordid>eNqFkUuLFDEQgBtxcR_6CwTJyVuPeXTnISgs6_qAhYV1PXgK6aRaMnZ32iQ9OP56086I4GWhIHX4qlL1VVU9J3hDMOGvtpsUTHQbirHcrIGbR9UZkULWomXsccnbFteCSnVanae0xZjxVtAn1SmRSnHByVnl7yOYPMKUUejRzmcz-gm9Qw7mAbIPEzJ9hojuwvKzhqlGX9E3k3L0FnX72aT0GhkUzeTC6H-BQ3MMaQab_Q6QHfzkrRlQwc3wtDrpzZDg2fG9qL68v76_-ljf3H74dHV5U9uG0Fx3nXWOYcuJaKFRnS3bMcuVFYpy6zrJqJG268E2xvKSKtlIwVvCRauM6tlF9fLQt4zyY4GU9eiThWEwE4Ql6cJR2VJRQHYAbZk5Rej1HP1o4l4TrFfDeqv_GNarYb0GbkrVi2P7pRvB_as5Ki3AmwMAZcmdh6iT9TBZcD4WMdoF_8AHb_-r_-vxO-whbcMSp-JPE52oxvrzeuT1xlhizCnD7DebzqP1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67528527</pqid></control><display><type>article</type><title>Treatment of vitamin D depletion after Roux-en- Y gastric bypass: a randomized prospective clinical trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Carlin, Arthur M., M.D ; Rao, D. Sudhaker, M.B.B.S., F.A.C.P., F.A.C.E ; Yager, Kelli M., M.S., M.P.H ; Parikh, Nayana J., B.Sc ; Kapke, Alissa, M.S</creator><creatorcontrib>Carlin, Arthur M., M.D ; Rao, D. Sudhaker, M.B.B.S., F.A.C.P., F.A.C.E ; Yager, Kelli M., M.S., M.P.H ; Parikh, Nayana J., B.Sc ; Kapke, Alissa, M.S</creatorcontrib><description>Abstract Background A high prevalence (60%) of vitamin D (VitD) depletion, defined as a serum 25-hydroxyvitamin D level of ≤20 ng/mL, is present in preoperative morbidly obese patients. Despite daily supplementation with 800 IU VitD and 1500 mg calcium after Roux-en- Y gastric bypass (RYGB), VitD depletion persists in almost one half (44%) of patients. However, the optimal management of VitD depletion after RYGB and the potential benefits of such treatment are currently unknown. Methods A total of 60 VitD-depleted morbidly obese women were randomly assigned to receive 50,000 IU of VitD weekly after RYGB (group 1; n = 30) or no additional VitD after RYGB (group 2; n = 30). All patients received a daily supplement of 800 IU VitD and 1500 mg calcium. The serum calcium, parathyroid hormone, 25-hydroxyvitamin D, bone-specific alkaline phosphatase, urinary N -telopeptide, and bone mineral density were measured preoperatively and 1 year after RYGB. Questionnaires were used to assess other potential sources of VitD, including sunlight exposure and ingestion of VitD-containing foods/liquids. Results At 1 year after RYGB, VitD depletion and mean 25-hydroxyvitamin D level had improved significantly in group 1 (14% and 37.8 ng/mL, respectively) compared with the values in group 2 (85% and 15.2 ng/mL, respectively; P <.001 for both). A significant 33% retardation in hip bone mineral density decline ( P = .043) and a significantly greater resolution of hypertension was seen in group 1 (75% versus 32%; P = .029). No significant adverse effects were encountered from pharmacologic VitD therapy. Conclusion The results of our study have shown that 50,000 IU of VitD weekly after RYGB safely corrects VitD depletion in most women, attenuates cortical bone loss, and improves resolution of hypertension.</description><identifier>ISSN: 1550-7289</identifier><identifier>EISSN: 1878-7533</identifier><identifier>DOI: 10.1016/j.soard.2008.08.004</identifier><identifier>PMID: 18996761</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Bariatric surgery ; Bone Density ; Bone mineral density ; Dietary Supplements ; Female ; Gastric Bypass ; Gastroenterology and Hepatology ; Humans ; Hypertension ; Metabolic bone disease ; Middle Aged ; Morbid obesity ; Obesity, Morbid - complications ; Obesity, Morbid - metabolism ; Obesity, Morbid - surgery ; Parathyroid hormone ; Parathyroid Hormone - blood ; Risk Factors ; Surgery ; Treatment Outcome ; Vitamin D - administration & dosage ; Vitamin D - analogs & derivatives ; Vitamin D - blood ; Vitamin D Deficiency - diagnosis ; Vitamin D Deficiency - drug therapy ; Vitamin D Deficiency - etiology ; Vitamin D depletion ; Vitamins - administration & dosage ; Weight Loss</subject><ispartof>Surgery for obesity and related diseases, 2009-07, Vol.5 (4), p.444-449</ispartof><rights>American Society for Metabolic and Bariatric Surgery</rights><rights>2009 American Society for Metabolic and Bariatric Surgery</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-bbcdd30c6175e49bc0083c69c7926cdb832a8cbfec4ac6a8c984876516759a9f3</citedby><cites>FETCH-LOGICAL-c412t-bbcdd30c6175e49bc0083c69c7926cdb832a8cbfec4ac6a8c984876516759a9f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1550728908006230$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18996761$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carlin, Arthur M., M.D</creatorcontrib><creatorcontrib>Rao, D. Sudhaker, M.B.B.S., F.A.C.P., F.A.C.E</creatorcontrib><creatorcontrib>Yager, Kelli M., M.S., M.P.H</creatorcontrib><creatorcontrib>Parikh, Nayana J., B.Sc</creatorcontrib><creatorcontrib>Kapke, Alissa, M.S</creatorcontrib><title>Treatment of vitamin D depletion after Roux-en- Y gastric bypass: a randomized prospective clinical trial</title><title>Surgery for obesity and related diseases</title><addtitle>Surg Obes Relat Dis</addtitle><description>Abstract Background A high prevalence (60%) of vitamin D (VitD) depletion, defined as a serum 25-hydroxyvitamin D level of ≤20 ng/mL, is present in preoperative morbidly obese patients. Despite daily supplementation with 800 IU VitD and 1500 mg calcium after Roux-en- Y gastric bypass (RYGB), VitD depletion persists in almost one half (44%) of patients. However, the optimal management of VitD depletion after RYGB and the potential benefits of such treatment are currently unknown. Methods A total of 60 VitD-depleted morbidly obese women were randomly assigned to receive 50,000 IU of VitD weekly after RYGB (group 1; n = 30) or no additional VitD after RYGB (group 2; n = 30). All patients received a daily supplement of 800 IU VitD and 1500 mg calcium. The serum calcium, parathyroid hormone, 25-hydroxyvitamin D, bone-specific alkaline phosphatase, urinary N -telopeptide, and bone mineral density were measured preoperatively and 1 year after RYGB. Questionnaires were used to assess other potential sources of VitD, including sunlight exposure and ingestion of VitD-containing foods/liquids. Results At 1 year after RYGB, VitD depletion and mean 25-hydroxyvitamin D level had improved significantly in group 1 (14% and 37.8 ng/mL, respectively) compared with the values in group 2 (85% and 15.2 ng/mL, respectively; P <.001 for both). A significant 33% retardation in hip bone mineral density decline ( P = .043) and a significantly greater resolution of hypertension was seen in group 1 (75% versus 32%; P = .029). No significant adverse effects were encountered from pharmacologic VitD therapy. Conclusion The results of our study have shown that 50,000 IU of VitD weekly after RYGB safely corrects VitD depletion in most women, attenuates cortical bone loss, and improves resolution of hypertension.</description><subject>Adult</subject><subject>Bariatric surgery</subject><subject>Bone Density</subject><subject>Bone mineral density</subject><subject>Dietary Supplements</subject><subject>Female</subject><subject>Gastric Bypass</subject><subject>Gastroenterology and Hepatology</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Metabolic bone disease</subject><subject>Middle Aged</subject><subject>Morbid obesity</subject><subject>Obesity, Morbid - complications</subject><subject>Obesity, Morbid - metabolism</subject><subject>Obesity, Morbid - surgery</subject><subject>Parathyroid hormone</subject><subject>Parathyroid Hormone - blood</subject><subject>Risk Factors</subject><subject>Surgery</subject><subject>Treatment Outcome</subject><subject>Vitamin D - administration & dosage</subject><subject>Vitamin D - analogs & derivatives</subject><subject>Vitamin D - blood</subject><subject>Vitamin D Deficiency - diagnosis</subject><subject>Vitamin D Deficiency - drug therapy</subject><subject>Vitamin D Deficiency - etiology</subject><subject>Vitamin D depletion</subject><subject>Vitamins - administration & dosage</subject><subject>Weight Loss</subject><issn>1550-7289</issn><issn>1878-7533</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUuLFDEQgBtxcR_6CwTJyVuPeXTnISgs6_qAhYV1PXgK6aRaMnZ32iQ9OP56086I4GWhIHX4qlL1VVU9J3hDMOGvtpsUTHQbirHcrIGbR9UZkULWomXsccnbFteCSnVanae0xZjxVtAn1SmRSnHByVnl7yOYPMKUUejRzmcz-gm9Qw7mAbIPEzJ9hojuwvKzhqlGX9E3k3L0FnX72aT0GhkUzeTC6H-BQ3MMaQab_Q6QHfzkrRlQwc3wtDrpzZDg2fG9qL68v76_-ljf3H74dHV5U9uG0Fx3nXWOYcuJaKFRnS3bMcuVFYpy6zrJqJG268E2xvKSKtlIwVvCRauM6tlF9fLQt4zyY4GU9eiThWEwE4Ql6cJR2VJRQHYAbZk5Rej1HP1o4l4TrFfDeqv_GNarYb0GbkrVi2P7pRvB_as5Ki3AmwMAZcmdh6iT9TBZcD4WMdoF_8AHb_-r_-vxO-whbcMSp-JPE52oxvrzeuT1xlhizCnD7DebzqP1</recordid><startdate>20090701</startdate><enddate>20090701</enddate><creator>Carlin, Arthur M., M.D</creator><creator>Rao, D. Sudhaker, M.B.B.S., F.A.C.P., F.A.C.E</creator><creator>Yager, Kelli M., M.S., M.P.H</creator><creator>Parikh, Nayana J., B.Sc</creator><creator>Kapke, Alissa, M.S</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090701</creationdate><title>Treatment of vitamin D depletion after Roux-en- Y gastric bypass: a randomized prospective clinical trial</title><author>Carlin, Arthur M., M.D ; Rao, D. Sudhaker, M.B.B.S., F.A.C.P., F.A.C.E ; Yager, Kelli M., M.S., M.P.H ; Parikh, Nayana J., B.Sc ; Kapke, Alissa, M.S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-bbcdd30c6175e49bc0083c69c7926cdb832a8cbfec4ac6a8c984876516759a9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Bariatric surgery</topic><topic>Bone Density</topic><topic>Bone mineral density</topic><topic>Dietary Supplements</topic><topic>Female</topic><topic>Gastric Bypass</topic><topic>Gastroenterology and Hepatology</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Metabolic bone disease</topic><topic>Middle Aged</topic><topic>Morbid obesity</topic><topic>Obesity, Morbid - complications</topic><topic>Obesity, Morbid - metabolism</topic><topic>Obesity, Morbid - surgery</topic><topic>Parathyroid hormone</topic><topic>Parathyroid Hormone - blood</topic><topic>Risk Factors</topic><topic>Surgery</topic><topic>Treatment Outcome</topic><topic>Vitamin D - administration & dosage</topic><topic>Vitamin D - analogs & derivatives</topic><topic>Vitamin D - blood</topic><topic>Vitamin D Deficiency - diagnosis</topic><topic>Vitamin D Deficiency - drug therapy</topic><topic>Vitamin D Deficiency - etiology</topic><topic>Vitamin D depletion</topic><topic>Vitamins - administration & dosage</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carlin, Arthur M., M.D</creatorcontrib><creatorcontrib>Rao, D. Sudhaker, M.B.B.S., F.A.C.P., F.A.C.E</creatorcontrib><creatorcontrib>Yager, Kelli M., M.S., M.P.H</creatorcontrib><creatorcontrib>Parikh, Nayana J., B.Sc</creatorcontrib><creatorcontrib>Kapke, Alissa, M.S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgery for obesity and related diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carlin, Arthur M., M.D</au><au>Rao, D. Sudhaker, M.B.B.S., F.A.C.P., F.A.C.E</au><au>Yager, Kelli M., M.S., M.P.H</au><au>Parikh, Nayana J., B.Sc</au><au>Kapke, Alissa, M.S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of vitamin D depletion after Roux-en- Y gastric bypass: a randomized prospective clinical trial</atitle><jtitle>Surgery for obesity and related diseases</jtitle><addtitle>Surg Obes Relat Dis</addtitle><date>2009-07-01</date><risdate>2009</risdate><volume>5</volume><issue>4</issue><spage>444</spage><epage>449</epage><pages>444-449</pages><issn>1550-7289</issn><eissn>1878-7533</eissn><abstract>Abstract Background A high prevalence (60%) of vitamin D (VitD) depletion, defined as a serum 25-hydroxyvitamin D level of ≤20 ng/mL, is present in preoperative morbidly obese patients. Despite daily supplementation with 800 IU VitD and 1500 mg calcium after Roux-en- Y gastric bypass (RYGB), VitD depletion persists in almost one half (44%) of patients. However, the optimal management of VitD depletion after RYGB and the potential benefits of such treatment are currently unknown. Methods A total of 60 VitD-depleted morbidly obese women were randomly assigned to receive 50,000 IU of VitD weekly after RYGB (group 1; n = 30) or no additional VitD after RYGB (group 2; n = 30). All patients received a daily supplement of 800 IU VitD and 1500 mg calcium. The serum calcium, parathyroid hormone, 25-hydroxyvitamin D, bone-specific alkaline phosphatase, urinary N -telopeptide, and bone mineral density were measured preoperatively and 1 year after RYGB. Questionnaires were used to assess other potential sources of VitD, including sunlight exposure and ingestion of VitD-containing foods/liquids. Results At 1 year after RYGB, VitD depletion and mean 25-hydroxyvitamin D level had improved significantly in group 1 (14% and 37.8 ng/mL, respectively) compared with the values in group 2 (85% and 15.2 ng/mL, respectively; P <.001 for both). A significant 33% retardation in hip bone mineral density decline ( P = .043) and a significantly greater resolution of hypertension was seen in group 1 (75% versus 32%; P = .029). No significant adverse effects were encountered from pharmacologic VitD therapy. Conclusion The results of our study have shown that 50,000 IU of VitD weekly after RYGB safely corrects VitD depletion in most women, attenuates cortical bone loss, and improves resolution of hypertension.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18996761</pmid><doi>10.1016/j.soard.2008.08.004</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1550-7289 |
| ispartof | Surgery for obesity and related diseases, 2009-07, Vol.5 (4), p.444-449 |
| issn | 1550-7289 1878-7533 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67528527 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Bariatric surgery Bone Density Bone mineral density Dietary Supplements Female Gastric Bypass Gastroenterology and Hepatology Humans Hypertension Metabolic bone disease Middle Aged Morbid obesity Obesity, Morbid - complications Obesity, Morbid - metabolism Obesity, Morbid - surgery Parathyroid hormone Parathyroid Hormone - blood Risk Factors Surgery Treatment Outcome Vitamin D - administration & dosage Vitamin D - analogs & derivatives Vitamin D - blood Vitamin D Deficiency - diagnosis Vitamin D Deficiency - drug therapy Vitamin D Deficiency - etiology Vitamin D depletion Vitamins - administration & dosage Weight Loss |
| title | Treatment of vitamin D depletion after Roux-en- Y gastric bypass: a randomized prospective clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T22%3A47%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20vitamin%20D%20depletion%20after%20Roux-en-%20Y%20gastric%20bypass:%20a%20randomized%20prospective%20clinical%20trial&rft.jtitle=Surgery%20for%20obesity%20and%20related%20diseases&rft.au=Carlin,%20Arthur%20M.,%20M.D&rft.date=2009-07-01&rft.volume=5&rft.issue=4&rft.spage=444&rft.epage=449&rft.pages=444-449&rft.issn=1550-7289&rft.eissn=1878-7533&rft_id=info:doi/10.1016/j.soard.2008.08.004&rft_dat=%3Cproquest_cross%3E67528527%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67528527&rft_id=info:pmid/18996761&rft_els_id=1_s2_0_S1550728908006230&rfr_iscdi=true |